Drug Search Results
More Filters [+]

Croscarmellose

Alternative Names: croscarmellose
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Belgium | Ireland | Taiwan | United Arab Emirates

Approved Indications: None

Known Adverse Events: None

Company: Collegium
Company Location: STOUGHTON MA 02072
Company CEO: Joseph Ciaffoni
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Croscarmellose

Countries in Clinic: Poland

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Atherosclerosis|Peripheral Arterial Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CADET-PAD

P3

Unknown Status

Atherosclerosis|Peripheral Arterial Disease

2026-02-03

Recent News Events